Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 5/20 | 0.40 |
| ▸ | CA12 | O43570 | 3/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 4/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28454875 | 1.00 | TDP1 (0.43) | TDP1MEN1GAAKMT2ACA2 | |
| SCHEMBL18262010 | 0.90 | TDP1 (0.50) | TDP1MEN1GAAKMT2ACA2 | |
| SCHEMBL18487257 | 0.90 | TDP1 (0.50) | TDP1MEN1GAAKMT2ACA2 | |
| SCHEMBL18262007 | 0.90 | TDP1 (0.50) | TDP1MEN1GAAKMT2ACA2 | |
| SCHEMBL13092290 | 0.83 | TDP1 (0.44) | TDP1MEN1GAAKMT2ACA2 | |
| SCHEMBL20437999 | 0.83 | TDP1 (0.44) | TDP1MEN1GAAKMT2ACA2 | |
| SCHEMBL19420087 | 0.83 | TDP1 (0.44) | TDP1MEN1GAAKMT2ACA2 | |
| SCHEMBL7131446 | 0.83 | TDP1 (0.44) | TDP1MEN1GAAKMT2ACA2 | |
| SCHEMBL661593 | 0.83 | TDP1 (0.49) | TDP1MEN1GAAKMT2ACA2 | |
| SCHEMBL18262802 | 0.83 | MEN1 (0.46) | TDP1MEN1GAAKMT2ACA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4007758-B1 | BIS-[N-((5-CARBAMOYL)-1H-BENZO[D]IMIDAZOL-2-YL)-PYRAZOL-5-CARBOXAMIDE] DERIVATIVES AND RELATED COMPOUNDS AS STING (STIMULATOR OF INTERFERON GENES) AGONISTS FOR THE TREATMENT OF CANCER | MERSANA THERAPEUTICS INC (US) | 2026-05-13 | — | — | EP | disclosed |
| EP-4673439-A1 | STING AGONISTS CONTAINING HYDRAZIDE, HYDRAZINE, AND HYDROXAMIC ACID FUNCTIONAL GROUPS | BioNTech SE (DE) | 2026-01-07 | — | — | EP | disclosed |
| EP-3919488-B1 | IMMUNOMODULATOR | HITGEN INC (CN) | 2025-08-27 | — | — | EP | disclosed |
| US-20250108048-A1 | STING AGONIST COMPOUNDS AND CONJUGATES | SUTRO BIOPHARMA, INC. | 2025-04-03 | — | — | US | disclosed |
| WO-2025029832-A2 | STING AGONIST COMPOUNDS AND CONJUGATES | SUTRO BIOPHARMA, INC. (US) | 2025-02-06 | — | — | WO | disclosed |
| US-20250011339-A1 | STING AGONIST COMPOUNDS AND METHODS OF USE | MERSANA THERAPEUTICS, INC. | 2025-01-09 | — | — | US | disclosed |
| WO-2024182414-A1 | STING AGONISTS CONTAINING HYDRAZIDE, HYDRAZINE, AND HYDROXAMIC ACID FUNCTIONAL GROUPS | BIONTECH US INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| US-11939343-B2 | Sting agonist compounds and methods of use | MERSANA THERAPEUTICS, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| EP-4007758-A1 | BIS-[N-((5-CARBAMOYL)-1H-BENZO[D]IMIDAZOL-2-YL)-PYRAZOL-5-CARBOXAMIDE] DERIVATIVES AND RELATED COMPOUNDS AS STING (STIMULATOR OF INTERFERON GENES) AGONISTS FOR THE TREATMENT OF CANCER | Mersana Therapeutics, Inc. (US) | 2022-06-08 | — | — | EP | disclosed |
| US-20220119379-A1 | IMMUNOMODULATOR | HITGEN INC. (CN) | 2022-04-21 | — | — | US | disclosed |
| US-20220064189-A1 | STING AGONIST COMPOUNDS AND METHODS OF USE | MERSANA THERAPEUTICS, INC. | 2022-03-03 | — | — | US | disclosed |
| CN-111499617-A | Immunomodulator | 成都先导药物开发股份有限公司 | 2020-08-07 | — | — | CN | disclosed |
| WO-2020156363-A1 | IMMUNOMODULATOR | 成都先导药物开发股份有限公司 | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250108048-A1 | STING AGONIST COMPOUNDS AND CONJUGATES | STING1, CGAS, MAVS | TDP1 136/4885MEN1 2370/4885GAA 243/4885 |
| US-11939343-B2 | Sting agonist compounds and methods of use | STING1, IRF3, MAVS | TDP1 194/4885MEN1 4317/4885GAA 1319/4885 |
| US-20220064189-A1 | STING AGONIST COMPOUNDS AND METHODS OF USE | STING1, IRF3, MAVS | TDP1 194/4885MEN1 4317/4885GAA 1319/4885 |
| US-20220119379-A1 | IMMUNOMODULATOR | STING1, TLR9, CGAS | TDP1 1184/4885MEN1 934/4885GAA 1822/4885 |
| US-20250011339-A1 | STING AGONIST COMPOUNDS AND METHODS OF USE | STING1, IRF3, MAVS | TDP1 194/4885MEN1 4317/4885GAA 1319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.